Saturday, October 31, 2026

OpenAI Scientist Envisions Autonomous Research Labs Operating in Data Centers for Months

OpenAI Chief Scientist Jakub Pachocki predicts AI models will soon conduct research autonomously for extended periods, functioning as "a whole research lab in a data center." The development raises governance challenges as 68 AI infrastructure companies reached unicorn status in early 2026, concentrating research capacity among organizations with massive computational resources.

LM Salvado
LM Salvado

March 23, 2026

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
OpenAI Scientist Envisions Autonomous Research Labs Operating in Data Centers for Months
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

OpenAI Chief Scientist Jakub Pachocki predicts AI models will soon enable "a whole research lab in a data center," with systems conducting research autonomously for extended periods—a capability that could reshape how scientific breakthroughs emerge globally.1

"I think we are getting close to a point where we'll have models capable of working indefinitely in a coherent way just like people do," Pachocki said.1 These systems would operate longer without human intervention, moving beyond current limitations on autonomous task completion.1

The infrastructure requirements are substantial. Pachocki advocates deploying the most powerful models in isolated sandboxes, disconnected from systems they could damage or exploit.1 This approach reflects growing international concern about AI systems with extended operational autonomy, particularly as different nations develop competing governance frameworks.

The prediction arrives as AI infrastructure investment accelerates globally. Early 2026 saw 68 companies reach unicorn status in the sector,2 while established players make strategic moves—S&P Global acquired energy AI firm Enertel AI to strengthen analytics capabilities. The venture capital landscape shows concentration among specialized investors backing this new unicorn class.2

Pachocki acknowledges the governance gap. "I think this is a big challenge for governments to figure out," he said, recognizing that industry self-regulation proves insufficient for systems operating at research-lab scale.1 This challenge extends across jurisdictions, with the U.S., EU, China, and other powers developing divergent regulatory approaches to advanced AI systems.

Automated research capabilities could compress development timelines across AI labs worldwide, potentially accelerating breakthroughs while concentrating research capacity among organizations with sufficient computational resources. The data center model favors players with infrastructure scale, raising questions about global access to cutting-edge AI research capabilities and whether smaller nations and institutions can compete.

The regulatory frameworks Pachocki identifies as necessary remain undeveloped internationally, creating a gap between technical capability and governance readiness that affects researchers, policymakers, and technology companies across borders.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMIT Technology Review
    OpenAI is throwing everything into building a fully automated researcher
  2. [2]News articleYahoo Finance· January 22, 2026
    4 Medical Supply Stocks Poised to Gain in a Prospering Industry
  3. [3]News articleYahoo Finance· February 24, 2026
    Agentic AI Foundation Welcomes 97 New Members As Demand for Open, Collaborative Agent Standardization Increases
  4. [4]Press releaseGlobeNewswire· March 13, 2026
    Agero Enters into Agreement to Acquire Urgently, for $5.50 in Cash Per Share, Expanding Tech-Driven Roadside Assistance Across Automotive, Fleet, Rental, and Insurance Markets
  5. [5]News articleYahoo Finance· November 26, 2025
    AI to Reshape the Global Technology Landscape in 2026, Says TrendForce
  6. [6]News articleMIT Technology Review
    Can quantum computers now solve health care problems? We’ll soon find out.
  7. [7]News articleYahoo Finance· January 30, 2026
    Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
  8. [8]News articleYahoo Finance· March 19, 2026
    Morning Brief: 3 big questions, 2 answers, and rate cut hopes remain alive
  9. [9]News articleYahoo Finance· March 17, 2026
    Nebius Teams With NVIDIA to Build Cloud for Robotics and Physical AI
  10. [10]News articleYahoo Finance· March 18, 2026
    S&P Global Acquires Enertel AI Corporation to Enhance Power Market Offering
  11. [11]News articleCrunchbase News
    The Rising Investors Behind The New Unicorn Class
  12. [12]Press releaseGlobeNewswire· March 19, 2026
    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com